Chinese Journal of Integrative Medicine

, Volume 12, Issue 2, pp 137–141 | Cite as

Effects of Yizhi Capsule on learning and memory disorder and β-amyloid peptide induced neurotoxicity in rats

  • Wu Hang-yu
  • Xu Jiang-pingEmail author
  • Li Lin
  • Zhu Bai-hua
Experimental Work and Research


Objective: To explore the effects of Yizhi Capsule (YZC) on learning and memory disorder and β-amyloid peptide induced neurotoxicity in rats.Methods: Various doses of YZC were administered to Sprague-Dawley (SD) rats for 8 consecutive days, twice a day. On the 8th day of the experiment, scopolamine hydrobromide was intraperitoneally injected to every rat and Morris water maze test and shuttle dark avoidance test were carried out respectively to explore the changes of learning and memory capacities in the rats. Besides, after the cerebral cortical neurons of newborn SD rats aged within 3 days were culturedin vitro for 7 days, drug serum containing YZC was added to the cultured neurons before or after β amyloid peptide25–35 (Aβ25–35) intoxication to observe the protective effect of YZC on neurotoxicity by MTT assay and to determine the LDH content in the supernatant.Results: Compared with those untreated with YZC, the rats having received YZC treatment got superiority in shorter time of platform seeking in Morris water maze test, as well as elongated latent period and less times of error in shuttle dark avoidance test. On the cultured neurons, YZC drug serum could effectively increase the survival rate of Aβ25–35 intoxicated neurons and reduce the LDH contents in cultured supernatant.Conclusion: YZC has an action of improving learning and memory disorder, and good protective effect on Aβ25–35 induced neurotoxicity in SD rats.

Key words

learning and memory disorder β-amyloid peptide neurotoxicity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Di Carlo A, Baldereschi M, Amaducci L, et al. Incidence of dementia, Alzheimer’s disease, and vascular dementia in Italy. The ILSA Study. J Am Geriatr Soc 2002; 50 (1): 41–48.CrossRefGoogle Scholar
  2. 2.
    Hebert LE, Beckett LA, Scherr PA, et al. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2005. Alzheimer Dis Assoc Disord 2001; 15(4): 169–173.PubMedCrossRefGoogle Scholar
  3. 3.
    Fillit HM, O’Connell AW, Brown WM, et al. Barriers to drug discovery and development for Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16(Suppl 1): S1–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Bai DL, Tang XC, He XC. Huperzine A, a potential therapeutic agent for treatment of Alzheimer’ s disease. Curr Med Chem 2000; 7(3): 355–374.PubMedGoogle Scholar
  5. 5.
    Xu JP, Yang XM. Development of active components of Chinese herbal medicine in the treatment of Alzheimer’s disease. J First Milit Med Univ 2001; 21 (Suppl): S53–58.Google Scholar
  6. 6.
    Xu JP, Wu HY, Li L. Effects of compound Yi-Zhi on D-galactose-induced learning and memory deficits in mice. Chin J Clin Pharmacol Ther 2003; 8(1): 31–34.Google Scholar
  7. 7.
    Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11 (1): 47–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Xu SY, Bian RL, Chen X, editors. Methodology of pharmacological experiments. 3rd ed. People’s Medical Publishing House, 2002: 826–828.Google Scholar
  9. 9.
    Bao JF, Liu GQ, editors. Advances in standardized methodology research on Chinese materia medica by seropharmacology. Prog Pharma Sci 2000; 24(2): 89-92.Google Scholar
  10. 10.
    Meyer SL, Lang DM, Forbes ME, et al. Production and characterization of recombinant mouse brain-derived neurotrophic factor and rat neurotrophin-3 expressed in insect cells. J Neurochem 1994; 62(3): 825–833.PubMedCrossRefGoogle Scholar
  11. 11.
    Pappolla MA, Simovich MJ, Thomas TB, et al. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J Pineal Res 2002; 32(3): 135–142.PubMedCrossRefGoogle Scholar
  12. 12.
    Deutsch JA. The cholinergic synapse and the site of memory. Science 1971; 174(11): 788–794.PubMedCrossRefGoogle Scholar
  13. 13.
    Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217(4558): 408–417.PubMedCrossRefGoogle Scholar
  14. 14.
    Ebert U, Oertel R, Wesnes KA, et al. Effects of physostigmine on scopolamine induced changes in quantitative electroencephalogram and cognitive performance. Hum Psychopharmacol 1998; 13(3): 199–210.CrossRefGoogle Scholar
  15. 15.
    Kopelman MD & Corn TH. Cholinergic “blockade” as a model for cholinergic depletion. Brain 1988; 111 (Pt5): 1079–1110.PubMedCrossRefGoogle Scholar
  16. 16.
    Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990; 250(4978): 279–282.PubMedCrossRefGoogle Scholar
  17. 17.
    Olson RE, Copeland RA, Seiffert D. Progress towards testing the amyloid hypothesis: inhibitors of APP processing. Curr Opin Drug Discov Devel 2001; 4(4): 390–401.PubMedGoogle Scholar

Copyright information

© The Chinese Journal of Integrated Traditional and Western Medicine Press 2006

Authors and Affiliations

  • Wu Hang-yu
    • 1
  • Xu Jiang-ping
    • 1
    Email author
  • Li Lin
    • 1
  • Zhu Bai-hua
    • 2
  1. 1.Department of PharmacologyFirst Military Medical UniversityGuangzhou
  2. 2.Qixing Pharmaceutical Co. Ltd.Guangzhou

Personalised recommendations